Valeant: Is the Rally Over?

Last week, Valeant Pharmaceuticals International (VRX) rallied after the drug maker unveiled an estimate-beating earnings report that reassure investor that it was making progresses rebuilding itself after following a series of investigations into the drug maker’s accounting and pricing practices. Also helping fuel the upswing, Valeant reduced its total debt by $6 billion since the […]
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>